Why CELC Stock Declined 15% in a Week Despite a Major FDA Win

Celcuity shares slid ~15% even after FDA approval of Revtorpyk, as investors focused on a late Q3 2026 launch. The timing implies delayed commercial sales and weaker near-term revenue visibility, weighing on the stock despite the regulatory milestone.